The influence of the introduction of biologic agents on surgical intervention in paediatric inflammatory bowel disease

Abstract

Objectives:
To determine how the use of biological therapy is associated with surgical intervention for paediatric inflammatory bowel disease (PIBD) at a population level.

Methods:
Hospital Episode Statistics data were obtained for all admissions within England (1997–2015), in children aged 0–18 years, with an ICD-10 code for diagnosis of Crohn disease (CD), ulcerative colitis (UC), or inflammatory bowel disease-unclassified (IBD-U). Office of Population Censuses and Surveys Classification of Surgical Operations and Procedures codes for major surgical resection associated with PIBD and for biological therapy were also obtained. Data are presented as median values (interquartile range).

Results:
In total, 22,645 children had a diagnosis of PIBD of which 13,722 (61%) had CD, 7604 (34%) had UC, and 1319 (5.8%) cases had IBD-U. Biological therapy was used in 4054 (17.9%) cases. Surgical resection was undertaken in 3212 (14%) cases, more commonly for CD than UC (17.5 vs 10.3%, P < 0.0001). Time from diagnosis to major surgical resection was 8.3 (1.2–28.2) months in CD and 8.2 (0.8–21.3) months in UC. As the time-frame of the dataset progressed, there was a decreased rate of surgical intervention (P = 0.04) and an increased use of biological therapy (P < 0.0001). Additionally, the number of new diagnoses of PIBD increased.

Conclusions:
The introduction of biologic agents has been associated with a reduction in cases undergoing surgery in children with a known diagnosis of PIBD. As time progresses we will be able to determine whether biological therapies prevent the need for surgery altogether or just delay this until adulthood.

More information

Identifiers

ORCID for James Ashton: orcid.org/0000-0003-0348-8198

ORCID for Nigel Hall: orcid.org/0000-0001-8570-9374

Catalogue record

Export record

Altmetrics